GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy

References

• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med. 1990;322:1561–1566.
   PubMed Web of Science ®Google Scholar
• Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the framingham study. J Am Coll Cardiol. 1993;22:6A–13A.
   PubMed Web of Science ®Google Scholar
• Powers SK, Smuder AJ, Kavazis AN, et al. Mechanisms of exercise-induced cardioprotection. Physiology. 2014;29:27–38.
   PubMed Web of Science ®Google Scholar
• Streicher JM, Ren S, Herschman H, et al. Mapk-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 2010;106:1434–1443.
   PubMed Web of Science ®Google Scholar
• Wende AR, O’Neill BT, Bugger H, et al. Enhanced cardiac akt/protein kinase b signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes. Mol Cell Biol. 2015;35:831–846.
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Ito M, Sato K, et al. Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol. 2005;38:375–385.
   PubMedGoogle Scholar
• Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: A novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90:1055–1063.
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527–537.
   PubMed Web of Science ®Google Scholar
• Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215–228.
   PubMed Web of Science ®Google Scholar
• Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004;322:1178–1191.
   PubMed Web of Science ®Google Scholar
• Booz GW, Day JN, Baker KM. Interplay between the cardiac renin angiotensin system and jak-stat signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol. 2002;34:1443–1453.
   PubMed Web of Science ®Google Scholar
• Iaccarino G, Barbato E, Cipolletta E, et al. Elevated myocardial and lymphocyte grk2 expression and activity in human heart failure. Eur Heart J. 2005;26:1752–1758.
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113:739–753.
   PubMed Web of Science ®Google Scholar
• Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993;60:405–430.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–211.
   PubMed Web of Science ®Google Scholar
• Brinks H, Boucher M, Gao E, et al. Level of g protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res. 2010;107:1140–1149.
   PubMed Web of Science ®Google Scholar
• Iaccarino G, Dolber PC, Lefkowitz RJ, et al. Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation. Hypertension. 1999;33:396–401.
   PubMed Web of Science ®Google Scholar
• Perrino C, Naga Prasad SV, Mao L, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547–1560.
   PubMed Web of Science ®Google Scholar
• Sato PY, Chuprun JK, Schwartz M, et al. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol Rev. 2015;95:377–404.
   PubMed Web of Science ®Google Scholar
• Belmonte SL, Blaxall BC. G protein-coupled receptor kinase 5: exploring its hype in cardiac hypertrophy. Circ Res. 2012;111:957–958.
   PubMed Web of Science ®Google Scholar
• Woodall MC, Ciccarelli M, Woodall BP, et al. G protein-coupled receptor kinase 2: A link between myocardial contractile function and cardiac metabolism. Circ Res. 2014;114:1661–1670.
   PubMed Web of Science ®Google Scholar
• Fusco A, Santulli G, Sorriento D, et al. Mitochondrial localization unveils a novel role for grk2 in organelle biogenesis. Cell Signal. 2012;24:468–475.
   PubMed Web of Science ®Google Scholar
• Sato PY, Chuprun JK, Ibetti J, et al. Grk2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levels. J Mol Cell Cardiol. 2015;89:360–364.
   PubMed Web of Science ®Google Scholar
• Johnson LR, Scott MG, Pitcher JA. G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Mol Cell Biol. 2004;24:10169–10179.
   PubMed Web of Science ®Google Scholar
• Johnson LR, Robinson JD, Lester KN, et al. Distinct structural features of g protein-coupled receptor kinase 5 (grk5) regulate its nuclear localization and DNA-binding ability. PloS one. 2013;8:e62508.
   PubMed Web of Science ®Google Scholar
• Penela P, Ruiz-Gomez A, Castano JG, et al. Degradation of the g protein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem. 1998;273:35238–35244.
   PubMed Web of Science ®Google Scholar
• Wu Z, Chen Y, Yang T, et al. Targeted ubiquitination and degradation of g-protein-coupled receptor kinase 5 by the ddb1-cul4 ubiquitin ligase complex. PloS one. 2012;7:e43997.
   PubMed Web of Science ®Google Scholar
• Luo J, Benovic JL. G protein-coupled receptor kinase interaction with hsp90 mediates kinase maturation. J Biol Chem. 2003;278:50908–50914.
   PubMed Web of Science ®Google Scholar
• Salcedo A, Mayor F Jr., Penela P. Mdm2 is involved in the ubiquitination and degradation of g-protein-coupled receptor kinase 2. Embo J. 2006;25:4752–4762.
   PubMed Web of Science ®Google Scholar
• Whalen EJ, Foster MW, Matsumoto A, et al. Regulation of beta-adrenergic receptor signaling by s-nitrosylation of g-protein-coupled receptor kinase 2. Cell. 2007;129:511–522.
   PubMed Web of Science ®Google Scholar
• Pronin AN, Benovic JL. Regulation of the g protein-coupled receptor kinase grk5 by protein kinase c. J Biol Chem. 1997;272:3806–3812.
   PubMed Web of Science ®Google Scholar
• Chuang TT, LeVine H 3rd, De Blasi A. Phosphorylation and activation of beta-adrenergic receptor kinase by protein kinase c. J Biol Chem. 1995;270:18660–18665.
   PubMed Web of Science ®Google Scholar
• Winstel R, Freund S, Krasel C, et al. Protein kinase cross-talk: membrane targeting of the beta-adrenergic receptor kinase by protein kinase c. Proc Natl Acad Sci USA. 1996;93:2105–2109.
   PubMed Web of Science ®Google Scholar
• Hu LA, Chen W, Premont RT, et al. G protein-coupled receptor kinase 5 regulates beta 1-adrenergic receptor association with psd-95. J Biol Chem. 2002;277:1607–1613.
   PubMed Web of Science ®Google Scholar
• Rockman HA, Choi DJ, Rahman NU, et al. Receptor-specific in vivo desensitization by the g protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA. 1996;93:9954–9959.
   PubMed Web of Science ®Google Scholar
• Hullmann JE, Grisanti LA, Makarewich CA, et al. Grk5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear nfat activity. Circ Res. 2014;115:976–985.
   PubMed Web of Science ®Google Scholar
• Sorriento D, Ciccarelli M, Santulli G, et al. The g-protein-coupled receptor kinase 5 inhibits nfkappab transcriptional activity by inducing nuclear accumulation of ikappab alpha. Proc Natl Acad Sci USA. 2008;105:17818–17823.
   PubMed Web of Science ®Google Scholar
• Martini JS, Raake P, Vinge LE, et al. Uncovering g protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA. 2008;105:12457–12462.
   PubMed Web of Science ®Google Scholar
• Huang ZM, Gao E, Fonseca FV, et al. Convergence of g protein-coupled receptor and s-nitrosylation signaling determines the outcome to cardiac ischemic injury. Sci Signal. 2013;6:ra95.
   PubMed Web of Science ®Google Scholar
• Penela P, Murga C, Ribas C, et al. The complex g protein-coupled receptor kinase 2 (grk2) interactome unveils new physiopathological targets. Br J Pharmacol. 2010;160:821–832.
   PubMed Web of Science ®Google Scholar
• Sorriento D, Santulli G, Franco A, et al. Integrating grk2 and nfkappab in the pathophysiology of cardiac hypertrophy. J Cardiovasc Transl Res. 2015;8:493–502.
   PubMed Web of Science ®Google Scholar
• Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of nf-kappab in the heart: to be or not to nf-kappab. Circ Res. 2011;108:1122–1132.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chen Y, Auger-Messier M, et al. Interaction between nfkappab and nfat coordinates cardiac hypertrophy and pathological remodeling. Circ Res. 2012;110:1077–1086.
   PubMed Web of Science ®Google Scholar
• Schlegel P, Reinkober J, Meinhardt E, et al. G protein-coupled receptor kinase 2 promotes cardiac hypertrophy. PloS one. 2017;12:e0182110.
   PubMed Web of Science ®Google Scholar
• Schumacher SM, Gao E, Cohen M, et al. A peptide of the rgs domain of grk2 binds and inhibits galpha(q) to suppress pathological cardiac hypertrophy and dysfunction. Sci Signal. 2016;9:ra30.
   PubMed Web of Science ®Google Scholar
• Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ark inhibitor. Science. 1995;268:1350–1353.
   PubMed Web of Science ®Google Scholar
• Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000–7005.
   PubMed Web of Science ®Google Scholar
• McKinsey TA. Derepression of pathological cardiac genes by members of the cam kinase superfamily. Cardiovasc Res. 2007;73:667–677.
   PubMed Web of Science ®Google Scholar
• Wei J, Joshi S, Speransky S, et al. Reversal of pathological cardiac hypertrophy via the mef2-coregulator interface. JCI Insight. 2017;2(17).
   Web of Science ®Google Scholar
• Chang S, McKinsey TA, Zhang CL, et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004;24:8467–8476.
   PubMed Web of Science ®Google Scholar
• Traynham CJ, Cannavo A, Zhou Y, et al. Differential role of g protein-coupled receptor kinase 5 in physiological versus pathological cardiac hypertrophy. Circ Res. 2015;117:1001–1012.
   PubMed Web of Science ®Google Scholar
• Islam KN, Bae JW, Gao E, et al. Regulation of nuclear factor kappab (nf-kappab) in the nucleus of cardiomyocytes by g protein-coupled receptor kinase 5 (grk5). J Biol Chem. 2013;288:35683–35689.
   PubMedGoogle Scholar
• Gold JI, Martini JS, Hullmann J, et al. Nuclear translocation of cardiac g protein-coupled receptor kinase 5 downstream of select gq-activating hypertrophic ligands is a calmodulin-dependent process. PloS one. 2013;8:e57324.
   PubMed Web of Science ®Google Scholar
• Cannavo A, Liccardo D, Eguchi A, et al. Myocardial pathology induced by aldosterone is dependent on non-canonical activities of g protein-coupled receptor kinases. Nat Commun. 2016;7:10877.
   PubMed Web of Science ®Google Scholar
• Keys JR, Greene EA, Cooper CJ, et al. Cardiac hypertrophy and altered beta-adrenergic signaling in transgenic mice that express the amino terminus of beta-ark1. Am J Physiol Heart Circulatory Physiol. 2003;285:H2201–2211.
   PubMed Web of Science ®Google Scholar
• Monto F, Oliver E, Vicente D, et al. Beta2- and beta1-adrenoceptor expression exhibits a common regulatory pattern with grk2 and grk5 in human and animal models of cardiovascular diseases. J Cardiovasc Pharmacol. 2015;66:478–486.
   PubMed Web of Science ®Google Scholar
• Klenke S, Engler A, Ecker D, et al. The grk2 promoter is regulated by early-growth response transcription factor egr-1. Basic Clin Pharmacol Toxicol. 2018;123:660–669.
   PubMed Web of Science ®Google Scholar
• Reid BG, Stratton MS, Bowers S, et al. Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. J Mol Cell Cardiol. 2016;97:106–113.
   PubMed Web of Science ®Google Scholar
• Braz JC, Bueno OF, De Windt LJ, et al. Pkc alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (erk1/2). J Cell Biol. 2002;156:905–919.
   PubMed Web of Science ®Google Scholar
• Park CH, Lee JH, Lee MY, et al. A novel role of g protein-coupled receptor kinase 5 in urotensin ii-stimulated cellular hypertrophy in h9c2ut cells. Mol Cell Biochem. 2016;422:151–160.
   PubMed Web of Science ®Google Scholar
• Choi DJ, Koch WJ, Hunter JJ, et al. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem. 1997;272:17223–17229.
   PubMed Web of Science ®Google Scholar
• Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1–6.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Circ J. 1963;27:282–293.
   Google Scholar
• Anderson KM, Eckhart AD, Willette RN, et al. The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (shhf) rats. Hypertension. 1999;33:402–407.
   PubMed Web of Science ®Google Scholar
• Yi XP, Gerdes AM, Li F. Myocyte redistribution of grk2 and grk5 in hypertensive, heart-failure-prone rats. Hypertension. 2002;39:1058–1063.
   PubMed Web of Science ®Google Scholar
• Cohn HI, Xi Y, Pesant S, et al. G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black americans. Hypertension. 2009;54:71–76.
   PubMed Web of Science ®Google Scholar
• Gros R, Benovic JL, Tan CM, et al. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest. 1997;99:2087–2093.
   PubMed Web of Science ®Google Scholar
• Raake PW, Vinge LE, Gao E, et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res. 2008;103:413–422.
   PubMed Web of Science ®Google Scholar
• Rengo G, Galasso G, Femminella GD, et al. Reduction of lymphocyte g protein-coupled receptor kinase-2 (grk2) after exercise training predicts survival in patients with heart failure. Eur J Prev Cardiol. 2014;21:4–11.
   PubMed Web of Science ®Google Scholar
• Gainetdinov RR, Bohn LM, Walker JK, et al. Muscarinic supersensitivity and impaired receptor desensitization in g protein-coupled receptor kinase 5-deficient mice. Neuron. 1999;24:1029–1036.
   PubMed Web of Science ®Google Scholar
• Gold JI, Gao E, Shang X, et al. Determining the absolute requirement of g protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ Res. 2012;111:1048–1053.
   PubMed Web of Science ®Google Scholar
• Cipolletta E, Campanile A, Santulli G, et al. The g protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc Res. 2009;84:407–415.
   PubMed Web of Science ®Google Scholar
• Anis Y, Leshem O, Reuveni H, et al. Antidiabetic effect of novel modulating peptides of g-protein-coupled kinase in experimental models of diabetes. Diabetologia. 2004;47:1232–1244.
   PubMed Web of Science ®Google Scholar
• Sorriento D, Santulli G, Fusco A, et al. Intracardiac injection of adgrk5-nt reduces left ventricular hypertrophy by inhibiting nf-kappab-dependent hypertrophic gene expression. Hypertension. 2010;56:696–704.
   PubMed Web of Science ®Google Scholar
• Sorriento D, Santulli G, Ciccarelli M, et al. The amino-terminal domain of grk5 inhibits cardiac hypertrophy through the regulation of calcium-calmodulin dependent transcription factors. Int J Mol Sci. 2018;19.
   PubMed Web of Science ®Google Scholar
• Kamal FA, Mickelsen DM, Wegman KM, et al. Simultaneous adrenal and cardiac g-protein-coupled receptor-gbetagamma inhibition halts heart failure progression. J Am Coll Cardiol. 2014;63:2549–2557.
   PubMed Web of Science ®Google Scholar
• Thal DM, Homan KT, Chen J, et al. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol. 2012;7:1830–1839.
   PubMed Web of Science ®Google Scholar
• Schumacher SM, Gao E, Zhu W, et al. Paroxetine-mediated grk2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med. 2015;7:277ra231.
   Web of Science ®Google Scholar
• Santulli G, Campanile A, Spinelli L, et al. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. Am J Cardiol. 2011;107:1125–1130.
   PubMedGoogle Scholar
• Homan KT, Wu E, Cannavo A, et al. Identification and characterization of amlexanox as a g protein-coupled receptor kinase 5 inhibitor. Molecules. 2014;19:16937–16949.
   PubMed Web of Science ®Google Scholar
• Tachibana H, Naga Prasad SV, Lefkowitz RJ, et al. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation. 2005;111:591–597.
   PubMed Web of Science ®Google Scholar
• Homan KT, Larimore KM, Elkins JM, et al. Identification and structure-function analysis of subfamily selective g protein-coupled receptor kinase inhibitors. ACS Chem Biol. 2015;10:310–319.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the mavi study. J Am Coll Cardiol. 2001;38:1829–1835.
   PubMed Web of Science ®Google Scholar
• Eckhart AD, Ozaki T, Tevaearai H, et al. Vascular-targeted overexpression of g protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol. 2002;61:749–758.
   PubMed Web of Science ®Google Scholar
• Liu S, Premont RT, Kontos CD, et al. A crucial role for grk2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005;11:952–958.
   PubMed Web of Science ®Google Scholar
• Keys JR, Zhou RH, Harris DM, et al. Vascular smooth muscle overexpression of g protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on gi-mediated signaling. Circulation. 2005;112:1145–1153.
   PubMed Web of Science ®Google Scholar
• Santulli G, Trimarco B, Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. High Blood Press Cardiovasc Prev. 2013;20:5–12.
   PubMedGoogle Scholar
• Han C, Li Y, Wang Y, et al. Development of inflammatory immune response-related drugs based on g protein-coupled receptor kinase 2. Cell Physiol Biochem. 2018;51:729–745.
   PubMed Web of Science ®Google Scholar
• Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991;88:8277–8281.
   PubMed Web of Science ®Google Scholar
• Houser SR, Margulies KB, Murphy AM, et al. Animal models of heart failure: A scientific statement from the american heart association. Circ Res. 2012;111:131–150.
   PubMed Web of Science ®Google Scholar
• Patten RD, Hall-Porter MR. Small animal models of heart failure: development of novel therapies, past and present. Circulation Heart Fail. 2009;2:138–144.
   PubMed Web of Science ®Google Scholar
• Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac beta ark1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A. 2001;98:5809–5814.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. National Library of Medicine (U.S.). Paroxetine-mediated grk2 inhibition to reduce cardiac remodeling after acute myocardial infarction (CARE-AMI). Identifier: NCT03274752. 2017 September. Retrieved from: https://ClinicalTrials.gov/show/NCT03274752
   Google Scholar